INCB18424: Phase I/II data

An open-label, dose-escalation, U.S. Phase I/II trial in 153 patients showed that 52% and 49% of patients who received 15 (n=33) or 25 (n=39) mg twice-daily INCB18424, respectively, for a median duration of 14.7 months had an objective response defined as a >=50% reduction in palpable spleen size. In patients who received 50 mg once-daily INCB18424 (n=22) or 10 mg twice daily (n=27), response rates were 41% and 30%, respectively. No patients who received 25 mg once-daily INCB18424 experienced clinical improvement. The MTD was 25 mg twice-daily or 100 mg once-daily INCB18424, with thrombocytopenia identified as the dose-limiting toxicity. Data were published in the New England Journal of Medicine. ...